Stockreport

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF IceCure is engaged with leading medical institutions throughout the U.S. looking to participate in the post-market study with the FDA-cleared ProSense®Clinical study sit [Read more]